[go: up one dir, main page]

WO2012013990A3 - Médicament destiné à soigner le psoriasis - Google Patents

Médicament destiné à soigner le psoriasis Download PDF

Info

Publication number
WO2012013990A3
WO2012013990A3 PCT/GR2011/000031 GR2011000031W WO2012013990A3 WO 2012013990 A3 WO2012013990 A3 WO 2012013990A3 GR 2011000031 W GR2011000031 W GR 2011000031W WO 2012013990 A3 WO2012013990 A3 WO 2012013990A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating psoriasis
losartan potassium
disease
medication
potassium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GR2011/000031
Other languages
English (en)
Other versions
WO2012013990A2 (fr
Inventor
Filoktitis Diakomanolis
Christos Gkilitsis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012013990A2 publication Critical patent/WO2012013990A2/fr
Publication of WO2012013990A3 publication Critical patent/WO2012013990A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'ensemble de produits contenant une substance efficace, losartan potassique, pour soigner le psoriasis. L'administration d'un médicament renfermant la substance efficace losartan potassique à une dose journalière de 100 milligrammes fait disparaître l'ensemble des symptômes de la maladie. Aucun des 21 patients ayant pris ce médicament n'a présenté de signe de toxicité, ni aucun autre effet secondaire.
PCT/GR2011/000031 2010-07-30 2011-08-01 Médicament destiné à soigner le psoriasis Ceased WO2012013990A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20100100426A GR1007516B (el) 2010-07-30 2010-07-30 Φαρμακο για την θεραπεια της νοσου της ψωριασης
GR20100100426 2010-07-30

Publications (2)

Publication Number Publication Date
WO2012013990A2 WO2012013990A2 (fr) 2012-02-02
WO2012013990A3 true WO2012013990A3 (fr) 2012-03-15

Family

ID=44872431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GR2011/000031 Ceased WO2012013990A2 (fr) 2010-07-30 2011-08-01 Médicament destiné à soigner le psoriasis

Country Status (2)

Country Link
GR (1) GR1007516B (fr)
WO (1) WO2012013990A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018024A2 (fr) * 2004-08-18 2006-02-23 Ace Aps Compositions cosmetiques et pharmaceutiques contenant des inhibiteurs de l'eca et/ou des antagonistes des recepteurs de l'angiotensine ii

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018024A2 (fr) * 2004-08-18 2006-02-23 Ace Aps Compositions cosmetiques et pharmaceutiques contenant des inhibiteurs de l'eca et/ou des antagonistes des recepteurs de l'angiotensine ii

Also Published As

Publication number Publication date
WO2012013990A2 (fr) 2012-02-02
GR1007516B (el) 2012-01-24

Similar Documents

Publication Publication Date Title
WO2007121913A3 (fr) Formulations en solution pharmaceutiques pour aérosols-doseurs pressurisés
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
AR085183A1 (es) Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
CU24117B1 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
CL2007003264A1 (es) Compuestos derivados de 1,4-benzotiepina 1,1-dioxido sustituidos con radicales bencilo; producto farmaceutico; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del sn
JO3146B1 (ar) مشتقات غير متجانسة الحلقية و استخدامها في علاج الاضطرابات العصبية
UY30282A1 (es) Compuestos quimicos
MX2014004479A (es) Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
MX2009004908A (es) Compuestos quimicos.
WO2010067078A3 (fr) Sels de xanthylium disubstitués en 3 et 6
MY156780A (en) Substituted aromatic compounds and pharmaceutical uses thereof
MX2011012643A (es) 2,4-diaminopiridinas para el tratamiento de enfermedades caracterizadas por la proliferacion celular excesiva o anormal.
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
WO2013040227A3 (fr) Composés thérapeutiques
WO2008146172A3 (fr) Composés présentant une activité antiparasitaire, leurs applications au traitement de maladies infectieuses provoquées par des apicomplexans
DK2802319T3 (da) Fastdosiskombinationsterapi for parkinsons sygdom
WO2010136035A3 (fr) Composés inédits modulant les récepteurs du calcium et leur utilisation pharmaceutique
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
AU2012308243A8 (en) Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11776011

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11776011

Country of ref document: EP

Kind code of ref document: A2